CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Capricor Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [1][2]. Group 1 - The investigation is centered on whether Capricor issued false or misleading statements or failed to disclose important information to investors [2]. - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Company's BLA for deramiocel [2].